Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO), announces the addition of Mass Spectrometry (Mass Spec) to its Analytical Development suite of services.

Oklahoma City, OK – June 14, 2019 – Cytovance® Biologics announced that it has received a notification letter and an Establishment Inspection Reports (EIRs) from the U.S. Food and Drug Administration (FDA) for its Oklahoma City site, FEI registration numbers: 3006341547.  The notification and the EIR are to close, under 21 CFR 20.64(d)(3), a Pre-Approval

OKLAHOMA CITY, May 09, 2018 (GLOBE NEWSWIRE) –– Cytovance® Biologics, Inc., a leading full-service biopharmaceutical contract development and manufacturing services company is pleased to announce the United States Food & Drug Administration (FDA) has concluded a successful Pre-License Inspection at Cytovance® with no 483 observations. The focus of the five-day PLI was quality systems, facilities,

OKLAHOMA CITY, February 13, 2018 (GLOBE NEWSWIRE) –– Cytovance® Biologics, Inc., a leading full-service biopharmaceutical contract manufacturer of mammalian and microbial biologics, announces completion of the first batch in new state-of-the-art 1000L microbial facility. “The Cytovance team has successfully completed our first run in our new state-of-the-art microbial facility,” said Michael O Mara, SVP of

Oklahoma City, OK July 24, 2017- Cytovance hosted an unannounced FDA inspection Tuesday, July 11th, 2017. The inspector conducted the inspection over an eight-day period and focused on Quality Systems. Overall the inspection was very positive and the inspector acknowledged that the site had already identified and taken action on most of the 4 observations.

Oklahoma City, OK – February 17, 2016 – Cytovance® Biologics, Inc. a leading full-service contract manufacturer of mammalian and microbial biologics announces expansion plans for Keystone Expression SystemTM. The Gram-negative bacterium, E. coli, is a true workhorse in the biopharmaceutical industry and has a well-established track record of FDA approval and commercialization. Despite its broad